MINNEAPOLIS, Feb. 25, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced there will be several presentations on the office-based Urgent PC Neuromodulation System at professional society meetings in February and March 2013.
Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), February 27 -March 2, 2013 in Las Vegas, NV
- "Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder Syndrome: Final 36-Month Results of the STEP Study" presented by Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI.
- "Clinical Insights into Percutaneous Tibial Nerve Stimulation (PTNS) vs. Sham Therapy for the Treatment of Overactive Bladder Syndrome (OAB): Secondary Analysis of the SUmiT Trial" presented by Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI.
- Neurostimulation Treatment for Overactive Bladder: An Evaluation of Cost Effectiveness Data" presented by Scott MacDiarmid, MD, Alliance Urology Specialists, Greensboro, NC.
David Kaysen, President and CEO of Uroplasty said, "Dr. Peters will present the final 3-year STEP study data that demonstrates sustained long term, clinically significant benefits for patients with overactive bladder (OAB) who responded to the initial 12-week Urgent PC therapy in the SUmiT study. These findings will also be published in the June edition of The Journal of Urology. He will also present additional data from the original randomized controlled SUmiT study that demonstrates Urgent PC efficacy in various subgroups."
"Dr. MacDiarmid will present the clinical and cost effectiveness of the office-based Urgent PC Neuromodulation System compared to surgically-implanted sacral nerve stimulation. While these therapies provide comparable clinical outcomes for patients, Urgent PC is substantially more cost effective. This is important information in today's cost-conscience health care environment," Mr. Kaysen added.
Society of Urologic Nurses (SUNA) Annual Symposium, March 7-9, 2013, Savannah, GA
Leslie Wooldridge, GNP, will present "Overactive Bladder: Evidence-Based Algorithm of Care" which includes Urgent PC as a treatment for OAB patients who are refractory to conservative therapy and OAB drug therapy.
"Ms. Wooldridge has long been an advocate for Urgent PC within her own practice focused on pelvic floor health and voiding dysfunction. Her presentation will review the recent AUA/SUFU Overactive Bladder Guidelines and the clinical evidence that was used to create them," continued Mr. Kaysen.
Southeastern Section of the AUA, March 14-16, 2013, Williamsburg, VA
Dr. Jamie Bartley, currently a Fellow in Female Pelvic Medicine and Reconstructive Surgery at Beaumont Hospital, Royal Oak, MI, will present "Clinical Insights into Percutaneous Tibial Nerve Stimulation (PTNS) vs. Sham Therapy for the Treatment of Overactive Bladder Syndrome (OAB): Secondary Analysis of the SUmiT Trial." Following the initial publication of the SUmiT study results, investigators analyzed the data for additional insights into patient benefits. This presentation will review those insights on patient demographics and how Urgent PC therapy was clinically effective.
"These presentations at professional society meetings continue to demonstrate the place for Urgent PC in the OAB algorithm of care and its adoption by healthcare providers. We are pleased to have this data presented at multiple professional society meetings as a way to deliver clinical evidence to additional providers," concluded Mr. Kaysen.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
Jenifer Kirtland (Investors)
Amy Phillips (Media)
SOURCE Uroplasty, Inc.